GENA-120 / Genome & Company - LARVOL DELTA

Targeting ITGB4 with a topoisomerase I ADC: Preclinical antitumor activity in colorectal and head and neck cancers (AACR 2026) - "It was well tolerated in mice at single doses up to 140 mg/kg, with no maximum tolerated dose reached and no dose-limiting toxicities observed. These robust preclinical data, demonstrating strong efficacy, favorable pharmacokinetics, excellent cross-species serum stability, and a promising safety profile, support the continued development of GENA-120 as a therapeutic candidate for ITGB4-expressing solid tumors, including colorectal and head & neck cancers."

ADC • Preclinical • Colorectal Cancer • Esophageal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • HMGB1 • ITGB4 • TOP1